- Home
- CLPR vs MREO Comparison
CLPR vs MREO Comparison
Compare CLPR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | MREO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8M | 52.5M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CLPR | MREO |
|---|---|---|
| Price | $3.00 | $0.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 47.7K | ★ 1.7M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.73% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,997,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $2.83 | $0.20 |
| 52 Week High | $4.61 | $2.94 |
Technical Indicators
Market Signals| Indicator | CLPR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 29.46 |
| Support Level | $2.95 | $0.20 |
| Resistance Level | $3.58 | $0.36 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 1.75 | 15.91 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).